Clinical Trials Logo

Atopic Dermatitis clinical trials

View clinical trials related to Atopic Dermatitis.

Filter by:

NCT ID: NCT03496974 Completed - Atopic Dermatitis Clinical Trials

A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

Start date: May 21, 2018
Phase: Phase 2
Study type: Interventional

A Phase 2 study of Bermekimab (MABp1) in patients with atopic dermatitis.

NCT ID: NCT03492398 Completed - Atopic Dermatitis Clinical Trials

A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis

Shaperon
Start date: January 29, 2018
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, placebo-controlled single and multiple dosing, dose escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209 gel after transdermal administration in healthy male volunteers as a possible treatment option for atopic dermatitis

NCT ID: NCT03490877 Completed - Atopic Dermatitis Clinical Trials

Scratch and Sleep Quantification in Atopic Dermatitis

SQUAD
Start date: July 13, 2018
Phase:
Study type: Observational

Atopic dermatitis (AD) is a chronic type of eczema affecting approximately 10% of adults and 12% of children in the US. The intense itching (pruritus) associated with AD can be significantly disruptive to sleep and quality of life for both the patients and their caregivers. AD is challenging to describe and measure. The purpose of this study is to see if we can reliably measure how much people with AD scratch and how scratching interferes with sleep and quality of life by using digital sensors, sleep studies and patient-reported information.

NCT ID: NCT03484897 Completed - Atopic Dermatitis Clinical Trials

Soothing and Barrier Restoration Activity of a Body Cream for Atopic Skin

Start date: January 12, 2018
Phase: N/A
Study type: Interventional

Open clinical study to evaluate the soothing activity of a body cream to be applied once a day, mono-laterally at level of the antecubital fold and forearm, for an uninterrupted period of 1 month, by 22 adult volunteers, with positive anamnesis for atopy and habitual itching.

NCT ID: NCT03443024 Completed - Atopic Dermatitis Clinical Trials

A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

Start date: January 30, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in participants with moderate-to-severe atopic dermatitis.

NCT ID: NCT03441568 Completed - Atopic Dermatitis Clinical Trials

In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control

Start date: September 26, 2018
Phase: N/A
Study type: Interventional

To investigate the safety and tolerability of the modified Diprobase formulation over 14 days in infants and children with a history of Atopic Dermatitis (AD).

NCT ID: NCT03435081 Completed - Atopic Dermatitis Clinical Trials

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

BREEZE-AD5
Start date: February 20, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis.

NCT ID: NCT03431610 Completed - Atopic Dermatitis Clinical Trials

A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis

Start date: November 13, 2017
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, 2-week study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of SB414 in subjects with mild to moderate AD.

NCT ID: NCT03428100 Completed - Atopic Dermatitis Clinical Trials

A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable

BREEZE-AD4
Start date: May 15, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of baricitinib in combination with topical corticosteroids in participants with moderate to severe atopic dermatitis who have experienced failure to cyclosporine or are intolerant to, or have contraindication to cyclosporine.

NCT ID: NCT03406117 Completed - Healthy Clinical Trials

A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests

Start date: April 1, 2016
Phase: Phase 4
Study type: Interventional

The objective of this clinical study is to assess the irritation and sensitisation potential of HAT1 topical products after repeated patch applications to healthy human participants by following conventional Repeated Insult (HRIPT), Cumulative Irritation (CIT), and Phototoxicity (PT) methodologies under the supervision of dermatologists.